Skip to main content
. 2019 Nov 12;10(61):6577–6588. doi: 10.18632/oncotarget.27312

Figure 3. The in vivo effect of Cisplatin and API-5 peptide in XBC-R (left panel) and XBC-S (right panel).

Figure 3

(A) The mice (n = 5 per treatment group) were treated with cisplatin (3 mg/kg) or anti-API-5 (2.4 mg/kg). The tumor volumes after 4 weeks of treatment showed an inhibition effect of anti-API-5 peptide on both XBC-R and XBC-S growth. (B) The anti-API-5 peptide effect on necrosis, angiogenesis, mitosis and apoptosis in XBC-R (n = 5). A significant difference was found for the extent of necrosis between absence of treatment and anti-API-5 peptide treatment at 2.4 mg/kg. Concerning angiogenesis, the CD31 positive cell count decreased by half with API-5 peptide treatment. Cell counts for the proliferation of KI67 positive cells also decreased significantly, by more than half. For apoptosis, caspase-3 cleaved positive cell counts increased with anti-API-5 peptide. * p versus control <0.05.